What's new? Log in Free sign up

Galmed Pharmaceuticals (GLMD) News and press releases

Company Profile

News

From Benzinga Pro

Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.

Galmed Reports Results From The Open-label Part Of The ARMOR Study

Biotech, News, FDA, General

Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in

Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.

Why Tuesday Morning Shares Are Trading Lower By 38%; Here Are 31 Stocks Moving Premarket

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Neptune Wellness Solutions Inc. (NASDAQ: NEPT) shares rose 106.9% to $0.5482 in pre-market trading on heavy volume.

Why ORIC Pharmaceuticals Shares Are Trading Higher By Around 46%; Here Are 27 Stocks Moving Premarket

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares rose 77.7% to $0.0906 in pre-market trading. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.

Press releases

From Benzinga Pro

Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol

Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.